Trial Profile
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 16 Feb 2024 Planned End Date changed from 31 Dec 2023 to 15 Jun 2027.
- 16 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 15 Jun 2024.
- 29 Aug 2023 Planned number of patients changed from 31 to 28.